← Retour au Screener

Sector: Santé
Open in Terminal → VTRSLive chart · Key metrics · News · Smart money

Viatris Inc.

VTRS Large Cap

Healthcare · Drug Manufacturers - Specialty & Generic

Mis à jour: Jun 18, 2026, 22:21 UTC

13,41 €
-2.29% aujourd'hui
52W: 7,53 € – 15,30 €
52W Low: 7,53 € Position: 75.7% 52W High: 15,30 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
5.77x
P/E prévisionnel
P/S Ratio
1.23x
Cours/Ventes
EV/EBITDA
7.49x
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
15,6 Md €
Capitalisation boursière
Croissance du CA
8.1%
Croissance du CA sur un an
Marge bénéficiaire
-2.04%
Marge nette
ROE
-1.96%
Rentabilité des capitaux propres
Beta
0.9
Sensibilité au marché
Positions vendeuses
3.54%
% du flottant vendu à découvert
Volume moyen
10,575,498
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
8 analysts
Avg. Price Target
15,54 €
+15.89% upside
Target Range
10,47 € – 20,07 €

About the Company

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Country: United States Employees: 30,000 Exchange: NMS

Viatris Inc. en bref

Viatris Inc. (VTRS) is currently trading at 13,41 € with a market capitalization of 15,6 Md €. The 52-week range spans from 7,53 € to 15,30 €; the current price is 12.3% below the yearly high. Year-over-year revenue growth stands at +8.1%.

💰 Dividende

Viatris Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Viatris Inc. (VTRS) au consensus : Acheter. L'objectif de cours moyen est de 15,54 €, soit un potentiel de +15.89% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 10,47 € à 20,07 €.

Viatris Inc. : la thèse d'investissement en détail

Viatris Inc. (VTRS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 15.89% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valorisation en contexte

With a PEG ratio of 0.15, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 7.49x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Thèse d'investissement : forces et faiblesses

Points forts
  • Consensus des analystes : Buy
  • Free cash flow positif
Points faibles
  • Actuellement non rentable

Aperçu technique

MM 50 jours
13,62 €
-1.54% vs. cours
MM 200 jours
11,29 €
+18.78% vs. cours
Sous le plus haut 52s
−12.3%
15,30 €
Au-dessus du plus bas 52s
+78.1%
7,53 €

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

Risque de marché (Bêta)
0.9 · Proche du marché
Évolue moins que le marché global
Positions vendeuses
3.54% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
99.67 · Modéré
Dette totale / capitaux propres

The data points to relatively defensive market behavior.

Trading Data

50-Day MA: 13,62 €
200-Day MA: 11,29 €
Volume: 19,553,824
Avg. Volume: 10,575,498
Short Ratio: 3.12
P/B Ratio: 1.2x
Debt/Equity: 99.67x
Free Cash Flow: 2,0 Md €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Viatris Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut